DDX21 Promotes Breast Cancer Growth and Metastasis via Stimulating RNAPII Elongation During Hypoxia

Abstract

Hypoxia is a hallmark of solid tumors, and hypoxia-inducible factors (HIFs) are the master transcription factors that allow cancer cells to sense and cope with a hypoxic microenvironment. However, the mechanism by which the HIF-mediated transcription process is precisely regulated remains poorly understood. Here, we demonstrate that the RNA helicase DDX21 facilitates breast tumor growth and metastasis by triggering HIF-mediated transcription elongation. Mechanistically, DDX21 induces the release of CDK9 from the 7SK complex, enhancing the interaction between CDK9 and HIF-1α. This interaction stimulates the transcription elongation of HIF target genes by elevating the enrichment of phosphorylated RNA Polymerase II at serine 2 on the hypoxia-response element of HIF target genes. These target genes, including IGFBP1, WNT1, WNT10B, TGFB1, PCK1, and SLC2A3, are critical for cancer cell proliferation and metastasis. Consequently, DDX21 enhances breast cancer cell proliferation, survival, migration, and invasion in vitro, and promotes breast tumor growth and metastasis in vivo. Importantly, DDX21 is highly expressed in breast tumors and correlates negatively with clinical outcomes in breast cancer patients. Our study reveals a novel mechanism of HIF regulation and positions DDX21 as a potential therapeutic target for disrupting the hypoxic adaptation machinery in breast cancer.

Keywords

breast cancer / DDX21 / hypoxia / RNA helicase / transcription elongation

References

[1] C. L. Chaffer and R. A. Weinberg, “A Perspective on Cancer Cell Metastasis,” Science 331, no. 6024 (2011): 1559–1564.

[2] E. B. Rankin and A. J. Giaccia, “Hypoxic Control of Metastasis,” Science 352, no. 6282 (2016): 175–180.

[3] G. L. Semenza, “The Hypoxic Tumor Microenvironment: A Driving Force for Breast Cancer Progression,” Biochimica et Biophysica Acta 1863, no. 3 (2016): 382–391.

[4] Y. Wang, X. Liu, W. Huang, J. Liang, and Y. Chen, “The Intricate Interplay Between HIFs, ROS, and the Ubiquitin System in the Tumor Hypoxic Microenvironment,” Pharmacology & Therapeutics 240 (2022): 108303.

[5] E. L. LaGory and A. J. Giaccia, “The Ever-expanding Role of HIF in Tumour and Stromal Biology,” Nature Cell Biology 18, no. 4 (2016): 356–365.

[6] G. L. Semenza, B. H. Jiang, S. W. Leung, et al., “Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1,” Journal of Biological Chemistry 271, no. 51 (1996): 32529–32537.

[7] C. B. Thompson, “Into Thin Air: How We Sense and Respond to Hypoxia,” Cell 167, no. 1 (2016): 9–11.

[8] Y. Chen, M. Liu, Y. Niu, and Y. Wang, “Romance of the Three Kingdoms in Hypoxia: HIFs, Epigenetic Regulators, and Chromatin Reprogramming,” Cancer Letters 495 (2020): 211–223.

[9] Y. Shi and D. M. Gilkes, “HIF-1 and HIF-2 in Cancer: Structure, Regulation, and Therapeutic Prospects,” Cellular and Molecular Life Sciences 82, no. 1 (2025): 44.

[10] J. W. Jeong, M. K. Bae, M. Y. Ahn, et al., “Regulation and Destabilization of HIF-1alpha by ARD1-mediated Acetylation,” Cell 111, no. 5 (2002): 709–720.

[11] Y. G. Yoo, G. Kong, and M. O. Lee, “Metastasis-associated Protein 1 Enhances Stability of Hypoxia-inducible Factor-1alpha Protein by Recruiting Histone Deacetylase 1,” EMBO Journal 25, no. 6 (2006): 1231–1241.

[12] J. H. Lim, Y. M. Lee, Y. S. Chun, et al., “Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-inducible Factor 1alpha,” Molecular Cell 38, no. 6 (2010): 864–878.

[13] R. Chen, M. Xu, R. T. Hogg, et al., “The Acetylase/Deacetylase Couple CREB-binding Protein/Sirtuin 1 Controls Hypoxia-inducible Factor 2 Signaling,” Journal of Biological Chemistry 287, no. 36 (2012): 30800–30811.

[14] L. Bao, Y. Chen, H. T. Lai, et al., “Methylation of Hypoxia-inducible Factor (HIF)-1alpha by G9a/GLP Inhibits HIF-1 Transcriptional Activity and Cell Migration,” Nucleic Acids Research 46, no. 13 (2018): 6576–6591.

[15] M. Long, Y. Zhu, Z. Chen, et al., “Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1alpha and microRNA-146a,” The Journal of Clinical Endocrinology & Metabolism 105, no. 7 (2020): 2237–2251.

[16] Z. Arany, L. E. Huang, R. Eckner, et al., “An Essential Role for p300/CBP in the Cellular Response to Hypoxia,” Proceedings of the National Academy of Sciences of the United States of America 93, no. 23 (1996): 12969–12973.

[17] J. L. Ruas, L. Poellinger, and T. Pereira, “Role of CBP in Regulating HIF-1-mediated Activation of Transcription,” Journal of Cell Science 118, no. Pt 2 (2005): 301–311.

[18] J. I. Perez-Perri, V. L. Dengler, K. A. Audetat, et al., “The TIP60 Complex Is a Conserved Coactivator of HIF1A,” Cell Reports 16, no. 1 (2016): 37–47.

[19] W. Luo, R. Chang, J. Zhong, A. Pandey, and G. L. Semenza, “Histone Demethylase JMJD2C Is a Coactivator for Hypoxia-inducible Factor 1 That Is Required for Breast Cancer Progression,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 49 (2012): E3367–3376.

[20] I. Mimura, M. Nangaku, Y. Kanki, et al., “Dynamic Change of Chromatin Conformation in Response to Hypoxia Enhances the Expression of GLUT3 (SLC2A3) by Cooperative Interaction of Hypoxia-inducible Factor 1 and KDM3A,” Molecular and Cellular Biology 32, no. 15 (2012): 3018–3032.

[21] Y. Du, J. Wang, M. Wang, et al., “NUSAP1 Recruits DAXX to Suppress HIF-Driven Triple-Negative Breast Cancer Progression,” Advanced Science 13, no. 5 (2026): e13380.

[22] Y. Wang, Y. Lyu, K. Tu, et al., “Histone Citrullination by PADI4 Is Required for HIF-dependent Transcriptional Responses to Hypoxia and Tumor Vascularization,” Science Advances 7, no. 35 (2021): eabe3771.

[23] S. Rocak and P. Linder, “DEAD-box Proteins: The Driving Forces Behind RNA Metabolism,” Nature Reviews: Molecular Cell Biology 5, no. 3 (2004): 232–241.

[24] H. Flores-Rozas and J. Hurwitz, “Characterization of a New RNA Helicase From Nuclear Extracts of HeLa Cells Which Translocates in the 5' to 3' direction,” Journal of Biological Chemistry 268, no. 28 (1993): 21372–21383.

[25] S. Wang, R. Yang, M. Song, et al., “Current Understanding of the Role of DDX21 in Orchestrating Gene Expression in Health and Diseases,” Life Sciences 349 (2024): 122716.

[26] K. Koltowska, K. S. Okuda, M. Gloger, et al., “The RNA Helicase Ddx21 Controls Vegfc-driven Developmental Lymphangiogenesis by Balancing Endothelial Cell Ribosome Biogenesis and p53 Function,” Nature Cell Biology 23, no. 11 (2021): 1136–1147.

[27] W. Wu, Y. Qu, S. Yu, et al., “Caspase-Dependent Cleavage of DDX21 Suppresses Host Innate Immunity,” mBio 12, no. 3 (2021): e0100521.

[28] E. Karyka, N. Berrueta Ramirez, and C. P. Webster, “SMN-deficient Cells Exhibit Increased Ribosomal DNA Damage,” Life Science Alliance 5, no. 8 (2022): e202101145.

[29] K. Wang, X. Yu, B. Tao, and J. Qu, “Downregulation of lncRNA HCP5 Has Inhibitory Effects on Gastric Cancer Cells by Regulating DDX21 Expression,” Cytotechnology 73, no. 1 (2021): 1–11.

[30] J. Cao, N. Wu, Y. Han, et al., “DDX21 promotes Gastric Cancer Proliferation by Regulating Cell Cycle,” Biochemical and Biophysical Research Communications 505, no. 4 (2018): 1189–1194.

[31] P. Lu, Z. Yu, K. Wang, et al., “DDX21 Interacts With WDR5 to Promote Colorectal Cancer Cell Proliferation by Activating CDK1 Expression,” Journal of Cancer 13, no. 5 (2022): 1530–1539.

[32] V. Putra, A. J. Hulme, A. E. Tee, et al., “The RNA-helicase DDX21 Upregulates CEP55 Expression and Promotes Neuroblastoma,” Molecular Oncology 15, no. 4 (2021): 1162–1179.

[33] D. S. Kim, C. V. Camacho, A. Nagari, et al., “Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21,” Molecular Cell 75, no. 6 (2019): 1270-1285 e1214.

[34] H. Zhang, Y. Zhang, C. Chen, et al., “A Double-negative Feedback Loop Between DEAD-box Protein DDX21 and Snail Regulates Epithelial-mesenchymal Transition and Metastasis in Breast Cancer,” Cancer Letters 437 (2018): 67–78.

[35] C. Song, A. Hotz-Wagenblatt, R. Voit, and I. Grummt, “SIRT7 and the DEAD-box Helicase DDX21 Cooperate to Resolve Genomic R Loops and Safeguard Genome Stability,” Genes & Development 31, no. 13 (2017): 1370–1381.

[36] E. Calo, R. A. Flynn, L. Martin, et al., “RNA Helicase DDX21 Coordinates Transcription and Ribosomal RNA Processing,” Nature 518, no. 7538 (2015): 249–253.

[37] Y. Zhang, K. C. Baysac, L. F. Yee, A. J. Saporita, and J. D. Weber, “Elevated DDX21 Regulates c-Jun Activity and rRNA Processing in human Breast Cancers,” Breast Cancer Research 16, no. 5 (2014): 449.

[38] F. X. Chen, E. R. Smith, and A. Shilatifard, “Born to Run: Control of Transcription Elongation by RNA Polymerase II,” Nature Reviews: Molecular Cell Biology 19, no. 7 (2018): 464–478.

[39] M. D. Galbraith, M. A. Allen, C. L. Bensard, et al., “HIF1A employs CDK8-mediator to Stimulate RNAPII Elongation in Response to Hypoxia,” Cell 153, no. 6 (2013): 1327–1339.

[40] Y. Chen, B. Zhang, L. Bao, et al., “ZMYND8 acetylation Mediates HIF-dependent Breast Cancer Progression and Metastasis,” Journal of Clinical Investigation 128, no. 5 (2018): 1937–1955.

[41] A. L. Harris, “Hypoxia—A Key Regulatory Factor in Tumour Growth,” Nature Reviews Cancer 2, no. 1 (2002): 38–47.

[42] E. E. Wicks and G. L. Semenza, “Hypoxia-inducible Factors: Cancer Progression and Clinical Translation,” Journal of Clinical Investigation 132, no. 11 (2022): e159839.

[43] Y. Wang, G. Li, M. Deng, et al., “The Multifaceted Functions of RNA Helicases in the Adaptive Cellular Response to Hypoxia: From Mechanisms to Therapeutics,” Pharmacology & Therapeutics 221 (2021): 107783.

[44] G. He, X. Peng, S. Wei, et al., “Exosomes in the Hypoxic TME: From Release, Uptake and Biofunctions to Clinical Applications,” Molecular Cancer 21, no. 1 (2022): 19.

[45] W. R. Wilson and M. P. Hay, “Targeting Hypoxia in Cancer Therapy,” Nature Reviews Cancer 11, no. 6 (2011): 393–410.

[46] A. Yfantis, I. Mylonis, G. Chachami, et al., “Transcriptional Response to Hypoxia: The Role of HIF-1-Associated Co-Regulators,” Cells 12, no. 5 (2023): 798.

[47] Y. P. Tsai, H. F. Chen, S. Y. Chen, et al., “TET1 regulates Hypoxia-induced Epithelial-mesenchymal Transition by Acting as a co-activator,” Genome Biology 15, no. 12 (2014): 513.

[48] Q. Liu, H. Geng, C. Xue, T. M. Beer, and D. Z. Qian, “Functional Regulation of Hypoxia Inducible Factor-1alpha by SET9 Lysine Methyltransferase,” Biochimica et Biophysica Acta 1853, no. 5 (2015): 881–891.

[49] B. M. Ortmann, N. Burrows, I. T. Lobb, et al., “The HIF Complex Recruits the Histone Methyltransferase SET1B to Activate Specific Hypoxia-inducible Genes,” Nature Genetics 53, no. 7 (2021): 1022–1035.

[50] Y. Chen, Y. Wang, and W. Luo, “ZMYND8 is a Primary HIF Coactivator That Mediates Breast Cancer Progression,” Molecular & Cellular Oncology 5, no. 4 (2018): e1479619.

[51] Y. Wang, Y. Chen, L. Bao, et al., “CHD4 Promotes Breast Cancer Progression as a Coactivator of Hypoxia-Inducible Factors,” Cancer Research 80, no. 18 (2020): 3880–3891.

[52] Y. Yang, H. Lu, C. Chen, et al., “HIF-1 Interacts With TRIM28 and DNA-PK to Release Paused RNA Polymerase II and Activate Target Gene Transcription in Response to Hypoxia,” Nature Communications 13, no. 1 (2022): 316.

[53] Y. K. Park, B. Park, S. Lee, et al., “Hypoxia-inducible Factor-2α-dependent Hypoxic Induction of Wnt10b Expression in Adipogenic Cells,” Journal of Biological Chemistry 288, no. 36 (2013): 26311–26322.

[54] S. I. Tazuke, N. M. Mazure, J. Sugawara, et al., “Hypoxia Stimulates Insulin-Like Growth Factor Binding Protein 1 (IGFBP-1) Gene Expression in HepG2 Cells: A Possible Model for IGFBP-1 Expression in Fetal Hypoxia,” Proceedings of the National Academy of Sciences of the United States of America 95, no. 17 (1998): 10188–10193.

[55] Y. W. Lin, X. F. Weng, B. L. Huang, et al., “IGFBP-1 in Cancer: Expression, Molecular Mechanisms, and Potential Clinical Implications,” American Journal of Translational Research 13, no. 3 (2021): 813–832.

[56] J. M. Ryniawec, M. R. Coope, E. Loertscher, et al., “GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors,” Diagnostics 12, no. 3 (2022): 676.

[57] X. X. Yao, Z. K. He, C. L. T. Qin, et al., “SLC2A3 promotes Macrophage Infiltration by Glycolysis Reprogramming in Gastric Cancer,” Cancer Cell International 20, no. 1 (2020): 503.

[58] K. Tang, L. Zhu, J. Chen, et al., “Hypoxia Promotes Breast Cancer Cell Growth by Activating a Glycogen Metabolic Program,” Cancer Research 81, no. 19 (2021): 4949–4963.

[59] B. C. Valdez, D. Henning, R. K. Busch, et al., “A Nucleolar RNA Helicase Recognized by Autoimmune Antibodies From a Patient With Watermelon Stomach Disease,” Nucleic Acids Research 24, no. 7 (1996): 1220–1224.

[60] N. R. Prabhakar and G. L. Semenza, “Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-inducible Factors 1 and 2,” Physiological Reviews 92, no. 3 (2012): 967–1003.

[61] Y. Z. Gu, S. M. Moran, J. B. Hogenesch, L. Wartman, and C. A. Bradfield, “Molecular Characterization and Chromosomal Localization of a Third Alpha-class Hypoxia Inducible Factor Subunit, HIF3alpha,” Gene Expression 7, no. 3 (1998): 205–213.

[62] N. Albadari, S. Deng, and W. Li, “The Transcriptional Factors HIF-1 and HIF-2 and Their Novel Inhibitors in Cancer Therapy,” Expert Opinion on Drug Discovery 14, no. 7 (2019): 667–682.

[63] S. Hara, J. Hamada, C. Kobayashi, Y. Kondo, and N. Imura, “Expression and Characterization of Hypoxia-inducible Factor (HIF)-3alpha in human Kidney: Suppression of HIF-mediated Gene Expression by HIF-3alpha,” Biochemical and Biophysical Research Communications 287, no. 4 (2001): 808–813.

[64] M. A. Maynard, H. Qi, J. Chung, et al., “Multiple Splice Variants of the human HIF-3 Alpha Locus Are Targets of the von Hippel-Lindau E3 Ubiquitin Ligase Complex,” Journal of Biological Chemistry 278, no. 13 (2003): 11032–11040.

[65] M. Zheng, S. Wang, K. Tang, et al., “The CYLD-PARP1 Feedback Loop Regulates DNA Damage Repair and Chemosensitivity in Breast Cancer Cells,” Proceedings of the National Academy of Sciences of the United States of America 122, no. 1 (2025): e2413890121.

[66] P. Jezequel, W. Gouraud, F. Ben Azzouz, et al., “bc-GenExMiner 4.5: New Mining Module Computes Breast Cancer Differential Gene Expression Analyses,” Database: The Journal of Biological Databases and Curation 2021 (2021): baab007.

[67] D. S. Chandrashekar, S. K. Karthikeyan, P. K. Korla, et al., “UALCAN: An Update to the Integrated Cancer Data Analysis Platform,” Neoplasia 25 (2022): 18–27.

[68] F. M. Buffa, A. L. Harris, C. M. West, and C. J. Miller, “Large Meta-analysis of Multiple Cancers Reveals a Common, Compact and Highly Prognostic Hypoxia Metagene,” British Journal of Cancer 102, no. 2 (2010): 428–435.

[69] S. C. Winter, F. M. Buffa, P. Silva, et al., “Relation of a Hypoxia Metagene Derived From Head and Neck Cancer to Prognosis of Multiple Cancers,” Cancer Research 67, no. 7 (2007): 3441–3449.

[70] B. Gyorffy, “Discovery and Ranking of the Most Robust Prognostic Biomarkers in Serous Ovarian Cancer,” Geroscience 45, no. 3 (2023): 1889–1898.

[71] H. Yuan, M. Yan, G. Zhang, et al., “CancerSEA: A Cancer Single-cell state Atlas,” Nucleic Acids Research 47, no. D1 (2019): D900–D908.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.